Alzheimers Disease: Advances in Etiology Pathogenesis and Therapeutics

Alzheimers Disease: Advances in Etiology Pathogenesis and Therapeutics

By: Sangram S. Sisodia (editor), Bengt Winblad (editor), Khalid Iqbal (editor)Hardback

1 - 2 weeks availability

Description

Alzheimera s Disease is an ever present problem affecting millions of people around the world and, as peoplea s average lifespan lengthens, its prevalence is set to increase. A global effort is needed to combat the disease, including research to investigate the causes, development of effective treatments and, ultimately, prevention of the disease. Published every two years, these timely books discuss the very latest research. This new volume provides a unique source of reference to the important work being done in this field, it gives academics and clinicians an opportunity to learn about cutting edge developments and covers all aspects of Alzheimera s Disease, including diagnosis, clinical course, epidemiological course and therapeutics and disease mechanisms. Alzheimera s Disease: Advances in Etiology, Pathogenesis and Therapeutics will provide essential information for basic and clinical researchers in Alzheimera s Disease and other dementias as well as for those who care for patients.

Create a review

Contents

List of Contributors. Dedications. Scientists Honored for Pioneering Research. Preface. Acknowledgments. PART I: EPIDEMIOLOGY AND RISK FACTORS. The Transition from Normal Functioning to Dementia in the Aging Population (L. Fratiglioni, et al.). Epidemiology of Alzheimera s Disease and Dementia: Advances and Challenges (R. Katzman). Epidemiology of Dementia in Downa s Syndrome (N. Schupf). PART II: GENETICS. A Genomic Search for Alzheimera s Disease Genes (J. Haines, et al.). Candidate Genes Showing No Evidence of Association with Alzheimera s Disease: Results of the NIMH--AD Genetics Initiative (L. Bertram, et al.). Familial Alzheimera s Disease with Spastic Paraparesis Associated with a Mutation at Codon 261 of the Presenilin 1 Gene (M. Farlow, et al.). Genetic Analysis of the Presenilin Pathway in Drosophila (I. Livne--Bar & G. Boulianne). Molecular Genetics and Transgenic Modeling of the Tauopathies (J. Lewis, et al.). Regulation of Four--repeat tau Expression: Interactions between Exon and Intron Splicing Regulatory Sequences (I. Da Souza & G. Schellenberg). PART III: DIAGNOSIS AND CLINICAL COURSE. Preclinical Prediction of AD: Relation Between Neuropsychological and Neuroimaging Findings (M. Albert, et al.). Neuropsychological Detection of Preclinical Alzheimera s Disease: Results of a Neuropathological Series of a Normala Controls (K. Welsh--Bohmer, et al.). Potentially Reversible Conditions in Memory Clinic Patients (A.--M. Hejl, et al.). The Alzheimera s Disease Centersa Neuropsychological Database Initiative: A Resource for Alzheimera s Disease Prevention Trials (M. Grundman, et al.). Mild Cognitive Impairment: Transition from Aging to Alzheimera s Disease (R. Petersen). Brain Functional Imaging in Early and Preclinical Alzheimera s Disease (A. Nordberg, et al.). Amyloid, PHF--tau, Ubiquitin and Synaptic Markers in the Progression of Alzheimera s Disease: Immunochemical Analyses of Frontal Cortex from Prospectively Studied Elderly Humans (D. Wang, et al.). Imaging the Consequences of Alzheimera s Disease Pathology (Y. Stern & S. Small). Influence of apoE Genotype and PET Brain Imaging on Preclinical Prediction of Alzheimera s Disease (G. Small, et al.). Overview of Vascular Dementia (W. Markesbery). Clinical and Imaging Characteristics of Vascular Dementia in a Memory Clinic (F. Pasquier, et al.). MRI of Entorhinal Cortex and Hippocampus in Alzheimera s Disease, Subcortical Ischemic Vascular Dementia and Mixed Dementia (N. Schuff, et al.). Olfactory Function and Event--related Potentials in Alzheimera s Disease (C. Murphy & C. Morgan). Phenotypic Differences in Cholinergic Markers within the Nucleus Basalis in Individuals with Mild Cognitive Impairment (E. Mufson, et al.). Evaluating CNS Biomarkers for Alzheimera s Disease (J. Growdon). CSF Markers for Early Alzheimera s Disease (K. Blennow, et al.). CSF--Phospho--tau (181P) as a Promising Marker for Discriminating Alzheimera s from Dementia with Lewy Bodies (E. Vanmechelen, et al.). Increased Levels of a Minor Glycoform of Acetylcholinesterase in Alzheimera s Disease Brain and Cerebrospinal Fluid (J. Saez--Valero, et al.). Plasma beta--Amyloid as a Surrogate Genetic Marker in Late--onset Alzheimera s Disease (N. Taner, et al.). Levels of Total and Deposited Abeta are Correlated with Dementia (S. Parvathy, et al.). What Should We Tell Patients Attending a Memory Disorders Clinic About Their Diagnosis? (C. Maguire & R. Slinn) PART IV: MECHANISMS OF NEURODEGENERATION. Innate Immunity, Autotoxicity and Degenerative Neurologies (P. McGeer, et al.). Neuroinflammatory Responses in the Alzheimera s Disease Brain Promote the Oxidative Post--translational Modification of Amyloid Deposits (C. Atwood, et al.). Plasma Antioxidants and Oxidative DNA Damage in Lymphocytes from Normal Aged People and Alzheimera s Disease Patients (P. Mecocci, et al.). Oxidative Damage and Antioxidant Responses in Alzheimera s Disease (G. Perry, et al.). Cyclooxygenase (COX)--2 and Clinical Progression of Alzheimera s Disease Dementia: Implications in the Role of Neuronal COX--2 in Cell Cycle (G. Pasinetti). Parallels between the Redox Properties and Toxicity of Abeta in Alzheimera s Disease and Mutant Cu/Zn--SOD in Familial Amyotrophic Lateral Sclerosis (A. Bush). beta--Amyloid Toxicity: Diverse Biological Activities Drive Multiple Cellular Mechanisms (C. Cotman, et al.). Mechanisms of Abeta Production and Abeta Degradation: Routes to the Treatment of Alzheimera s Disease (D. Selkoe, et al.). A High Fat, High Cholesterol Diet Accelerates beta--Amyloid Accumulation in the CNS of a Transgenic Mouse Model of Alzheimera s Disease (L. Refolo, et al.). Electron Microscopy and X--ray Diffraction Studies further Confirm the Efficacy of PTI--00703TM(R) (Cata s Claw Derivative) as a Potential Inhibitor of Alzheimera s beta--Amyloid Protein Fibrillogenesis (G. Castillo, et al.). Accelerated Abeta Generation in a Cell Model of Alzheimera s Disease--related Endosomal--Lysosomal System Upregulation (P. Mathews, et al.). The Amyloid Precursor Protein V717I Mutation Increases Susceptibility to Cell Death in a Cholesterol--dependent Manner (L. Puglielli, et al.). Intracellular and Secreted Abeta 42/40 Ratios Are Differently Influenced by APP Mutations (H. Grimm, et al.). Familial British Dementia (J. Ghiso, et al.). Cellular Metabolism of Familial British Dementia--associated BRI--L (S.--H. Kim & S. Sisodia). A Decamer Duplication in the BRI Gene Originates a de novo Amyloid Peptide that Causes Dementia in a Danish Kindred (R. Vidal, et al.). Familial Alzheimera s Disease--linked Mutant Presenilins Attenuate Capacitative Calcium Entry (I. Cheng, et al.). Presenilin--1 Is a Regulatory Component of the Cadherin CellAdhesion Complex: Implications for Alzheimera s Disease (A. Georgakopoulos, et al.). Presenilins and Notch Signaling Pathway (W. Song & B. Yankner). Functional Consequences of the Association of PSI with beta--Catenin (S. Soriano, et al.). A Novel Protease Active Site Motif Conserved in Presenilins and Polytopic Bacterial Aspartyl Proteases? (H. Steiner & C. Haass). The Unfolded Protein Response--mediated Upregulation of BiP and CHOP Is not Affected by Presenilin Expression (N. Sato & G. Thinakaran). Mechanisms of alpha--Synuclein and NAC Fibrillogenesis (M. Hashimoto, et al.). Neurofibrillary Degeneration: Patterns of Tau Isoform Expression (A. Delacourte). Phosphorylation, Microtubule Binding and Aggregation of Tau Protein in Alzheimera s Disease (J. Avila, et al.). Phosphorylation of Protein Tau and Rescue of Protein Tau--induced Axonopathy by GSK--3beta in GSK--3betaxhtau40 Double Transgenic Mice (K. Spittaels, et al.). Pathogenic Implication of Altered Tau Properties Caused by FTDP--17 Mutations (P. Nacharaju, et al.). A Hexapeptide Motif (306VQIVYK311)--forming beta Structure Indues the Aggregation of Tau Protein to Paired Helical Filaments (M. von Bergen, et al.). PART V: ANIMAL AND CELLULAR MODELS. Formation of Neurofibrillary Tangles in Mouse Brain (A. Takashima & K. Tanemura). Inducible Transgenic Expression of Wild--type tau in H4 Neuroglioma Cells (M. DeTure, et al.). Lewy--like Pathology in Mice Transgenic for Mutant (A53T) and Wild--type Human alpha--Synuclein (B. Sommer, et al.). Somal and Neuritic Accumulation of the Parkinsona s Disease--associated Mutant [A30P]a--Synuclein in Transgenic Mice (P. Kahle, et al.). Ex vivo Transmission of Mouse--adapted Prion Strains to N2a and GT1--7 Cell Lines (S. Lehmann, et al.). In Vivo Perturbation of Lysosomal Function Promotes Neurodegeneration in the PS1M146v/APPk670N,M671L Mouse Model of Alzheimera s Disease Pathology (R. Nixon, et al.). Changes in Cognitive Characteristics of Tg(APP) CRND8 Mice at Early Stages of Immunization with Beta--Amyloid Peptide (C. Janus, et al.). PART VI: THERAPEUTICS AND THERAPEUTIC STRATEGIES. Galantamine, a Novel Treatment for Alzheimera s Disease: A Review of Long--term Benefits to Patients and Caregivers (P. Tariot & B. Winblad). Benefits of Donepezil on Cognition, Function and Neuropsychiatric Symptoms in Patients with Mild and Moderate Alzheimera s Disease over One Year (G. Waldemar, et al.). Characterization of Alzheimera s beta--Secretase Protein BACE: Processing and Other Post--translational Modifications (M. Haniu, et al.). Androgen Treatment Reduces Cognitive Deficits in Female apoE4 Transgenic Mice (J. Raber, et al.). Studies with the Memory--enhancing Drug AIT--082 in PC12 Cells (D. Lahiri, et al.). Generation of Auto--antibodies toward Alzheimera s Disease Vaccination (B. Solomon & D. Frenkel). Toward the Identification of y--Secretase: Using Transition State Analog Inhibitors (W. Esler, et al.). Photoactivated, Active--site--directed gamma--Secretase Inhibitors Covalently Label Presenilin 1 (S. Gardell, et al.). Functional Analysis of beta--Secretase Using Mutagenesis and Structural Homology Modeling (G. Tatsuno, et al.). Therapeutic Approaches to Prion Diseases: In Vitro Studies with Tetracycline Compounds (T. Awan, et al.). PART VII: PSYCHOSOCIAL CARE. Influence of a Memory Training Program on Attention and Memory Performance of Patients with Dementia (T. Bernhardt, et al.). Prediction of Use of Emergency Community Services by Cognitively Impaired Seniors who Live Alone: Preliminary Findings of a Prospective Study (M. Tierney, et al.). Index.

Product Details

  • publication date: 28/03/2001
  • ISBN13: 9780471521761
  • Format: Hardback
  • Number Of Pages: 888
  • ID: 9780471521761
  • weight: 1276
  • ISBN10: 0471521760

Delivery Information

  • Saver Delivery: Yes
  • 1st Class Delivery: Yes
  • Courier Delivery: Yes
  • Store Delivery: Yes

Prices are for internet purchases only. Prices and availability in WHSmith Stores may vary significantly

Close